Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom.
Saved in:
| Title: | Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. |
|---|---|
| Authors: | Lo SH; Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Road, WC1X 8NL, London, UK., Gorni K; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Sutherland CS; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Martí Y; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Lloyd A; Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Road, WC1X 8NL, London, UK. andrew.lloyd@acasterlloyd.com., Paracha N; F. Hoffmann-La Roche Ltd, Basel, Switzerland. |
| Source: | PharmacoEconomics [Pharmacoeconomics] 2022 Apr; Vol. 40 (Suppl 1), pp. 91-102. Date of Electronic Publication: 2021 Oct 18. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
